Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes

Pollex, Rebecca L.; Mamakeesick, Mary; Zinman, Bernard; Harris, Stewart B.; Hanley, Anthony J. G.; Hegele, Robert A.
January 2005
Cardiovascular Diabetology;2005, Vol. 4, p17
Academic Journal
Background: Individuals with diabetes are twice as likely to develop peripheral arterial disease (PAD), the manifestation of extensive atherosclerosis throughout the lower extremities. One putative determinant of PAD is the 677C>T polymorphism in the gene encoding methylenetetrahydrofolate reductase (MTHFR), which has previously been found to associate with various diabetic complications including retinopathy, nephropathy, atherosclerosis and coronary heart disease. The objective of this study was to investigate a possible role for the MTHFR 677C>T gene polymorphism with PAD in subjects with type 2 diabetes from an isolated aboriginal Canadian population. Methods: The 677C>T MTHFR gene polymorphism was genotyped in 138 subjects of Oji-Cree descent. Participants were selected from a community-wide survey that included PAD assessment by ankle-brachial index (ABI) measurement, and also intermittent claudication assessment by the Rose questionnaire. Results: MTHFR 677T allele carriers had an increased risk of PAD with an odds ratio of 3.54 (95% CI 1.01, 12.4), P = 0.049, after adjustment for age, sex, duration of diabetes, hypertension, current smoking habits, and use of insulin or oral treatment for diabetes. None of these additional covariables was significantly associated with PAD. No association was found between MTHFR genotype and intermittent claudication. Conclusion: The genetic influence of the MTHFR 677C>T genotype on diabetic PAD is modest, yet for the Oji-Cree it is a major risk factor in comparison to other traditional risk factors.


Related Articles

  • Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Li Jin Pu; Lin Lu; Xue Wei Xu; Rui Yan Zhang; Qi Zhang; Jian Sheng Zhang; Jian Hu; Zheng Kun Yang; Feng Hua Ding; Qiu Jin Chen; Sheng Lou; Jie Shen; Dan Hong Fang; Wei Feng Shen // Cardiovascular Diabetology;2006, Vol. 5, p27 

    Background: Coronary artery disease (CAD) is a major vascular complication of diabetes mellitus and reveals high mortality. Up to 30% of diabetic patients with myocardial ischemia remain asymptomatic and are associated with worse prognosis compared to non-diabetic counterpart, which warrants...

  • Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance. Watson, Karol E.; Harmel, Anne L. Peters; Matson, Gary; Peters Harmel, Anne L // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2003, Vol. 8 Issue 4, p253 

    Type 2 diabetes mellitus is associated with a marked increase in the risk of atherosclerotic diseases, including coronary heart disease, peripheral arterial disease, and cerebrovascular disease. Insulin resistance is a key factor in the pathogenesis of type 2 diabetes mellitus. Insulin...

  • Dynamic Role of Microparticles in Type 2 Diabetes Mellitus. Nomura, Shosaku // Current Diabetes Reviews;2009, Vol. 5 Issue 4, p245 

    Type 2 diabetes mellitus increases the risk of cerebro/cardiovascular events, since this disease leads to the development of premature atherosclerosis and atherothrombosis associated with diabetes accelerates diabetic macroangiopathy. Microparticles (MPs) released from cells (MPs) may play a...

  • Osteoprotegerin Is Associated With Silent Coronary Artery Disease in High-Risk but Asymptomatic Type 2 Diabetic Patients. Avignon, Antoine; Sultan, Ariane; Piot, Christophe; Elaerts, Stéphane; Cristol, Jean Paul; Dupuy, Anne Marie // Diabetes Care;Sep2005, Vol. 28 Issue 9, p2176 

    OBJECTIVE -- Osteoprotegerin (OPG) is an inhibitor of osteoclastogenesis, which has been recently involved in atherosclerosis. The relationship between coronary atherosclerosis and OPG has never been studied in asymptomatic type 2 diabetic patients. RESEARCH DESIGN AND METHODS -- This is a...

  • Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients.  // Cardiovascular Diabetology;2011, Vol. 10 Issue 1, p41 

    The article offers information on the research conducted by the authors related to the association of increased serum myeloid-related protein level and atherosclerosis in type 2 diabetic patients. It states that the study evaluated the correlation between serum levels, endogenous secretory...

  • Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.  // Cardiovascular Diabetology;2011, Vol. 10 Issue 1, p76 

    The article offers information on the research conducted by the authors related to plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. It states that Cardiovascular disease (CVD) is frequent in type 2 diabetes...

  • P210 Study of silent myocardial ischemia in type 2 diabetic males: upper egypt experience. Kassem, A M; Kishk, YHIA; Hassan, ALI; Abdelwahab, MHAMED // Cardiovascular Research;Jul2014, Vol. 103 Issue suppl_1, pS37 

    Purpose: Accelerated atherosclerosis is one of the most common complications of diabetes mellitus. A crucial aspect of coronary artery disease in this situation is its silent nature.Aim of the work: To detect the prevalence of silent myocardial ischemia (SMI) in type 2 diabetic males in Upper...

  • PRECALENCE AND CLINICAL PREDICTORS OF SILENT MYOCARDIAL ISCHEMIA IN PATIENTS WITH TYPE 2 DIABETES. Anand, D.V.; Lim, E.; Hopkins, D.; Sharp, P.; Fourie, S.; Raval, U.; Lipkin, D.; Corder, R.; Lahiri, A. // Heart;May2004 Supplement 3, Vol. 90, pA9 

    The article presents a study of the prevalence and clinical predictors of silent myocardial ischaemia (SMI) in patients with type 2 diabetes. Coronary artery disease is the leading cause of death in patients with type 2 diabetes, but is often silent. Consequently, it may be far advanced at the...

  • New Study on Thiazolidinediones May Show Benefits. Elliott, William T. // Clinical Oncology Alert;Jun2008, Vol. 24 Issue 6, p1 

    The article discusses the results of a study which compares pioglitazone with sulfonylurea glimepiride measuring the progression of coronary atherosclerosis in patients with type 2 diabetes. Based on the study, glimepiride increased percent change in atheroma volume (PAV) by 0.73% while...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics